FDA OKs BeiGene’s zanubrutinib for mantle cell lymphoma

The FDA grants accelerated approval to BeiGene’s (BGNE -0.6%) BTK inhibitor zanubrutinib, branded as Brukinsa, for the treatment of mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma, its first approved drug in the U.S.

Zanubrutinib had Breakthrough Therapy and Orphan Drug status for the indication.

https://seekingalpha.com/news/3519412-fda-oks-beigenes-zanubrutinib-mantle-cell-lymphoma